CrisPRO Blog
Insights, news, and research at the intersection of AI and oncology.
Featured Article
Part 2 — NCT02264678 CAPRI: Ceralasertib + Olaparib and the BRCA resistance problem.
**Trial:** NCT02264678 (CAPRI) **Drugs:** Ceralasertib (ATRi) + Olaparib (PARPi) **Cancer:** Recurrent high-grade serous ovarian carcinoma (HGSOC) **Published:** Drew et al., *JCO* 2022 **CrisPRO delta:** **+0.108** ·
Series · 4 parts
Platinum Window Hypothesis
Read in order — each part builds on the last.
- Part 1Apr 9, 2026
Part 1: The Signal We Weren't Looking For: Metformin
You probably know Metformin as a diabetes drug. Costs $7 to $15 a month at any pharmacy. Been around since the 1950s. About as glamorous as a glass of water. But our engine kept ranking it unusually high for ovarian cancer. The IC50 scores were credible. The mechanism was real. And when we dug into the published literature, we found something that genuinely surprised us.
Read part 1 - Part 2Apr 9, 2026
Part 2: Who is the system failing most, and why?
We built a computational engine and pointed it at 427 real ovarian cancer patients. We asked one question: who is the system failing most, and why?
Read part 2 - Part 3Apr 9, 2026
Part 3: The Clock We Didn't Know Was Running
Two trials failed last year. Not because the drugs didn't work. Because nobody knew what time it was.
Read part 3 - Part 4Apr 9, 2026
Part 4: 2,500 Patients Just Told Us The Same Thing
We took two genes — FAP and CXCL10 — and asked a simple question in each cohort: do patients with FAP below their cohort average and CXCL10 above their cohort average live longer than everyone else?
Read part 4
Also on the blog
April 18, 2026
Part 1: Adavosertib — NCT03579316 (CrisPRO, WEE1, and PTEN Loss)
**Trial:** NCT03579316 **Drug:** Adavosertib (AZD1775) — WEE1 kinase inhibitor **Combination:** + Gemcitabine **Cancer:** Recurrent/refractory solid tumors (ovarian focus) **Published:** JCO 2023 — PMID referenced in CrisPRO validation run **CrisPRO delta:** **+0.307** — strongest of all 5 validations